JAC Advance Access published online on January 5, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki458
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Infectious Diseases, University of Turin, Turin, Italy
* To whom correspondence should be addressed. Objectives: The optimal regimen for acute hepatitis C (AHC) is considered to be a 24 week treatment with interferon (IFN) alpha-2b. A 24 week treatment with pegylated IFN (PEG-IFN) alpha-2b is also effective. This study was designed to assess response rates to a 12 week regimen of PEG-IFN alpha-2b. Patients and methods: Patients with AHC were treated with PEG-IFN alpha-2b for 12 weeks in an open, non-randomized, prospective cohort study. Diagnosis of AHC was made with positive serum HCV RNA and elevated alanine aminotransferase (ALT) levels with a documented seroconversion or a known risk factor in the preceding 6 months. Treatment was administered within a median of 31 days (range 0-116) of the ALT level peak at a dosage varying from 1.06 to 1.66 µg/kg/week. The primary end-point was a sustained virological response (SVR). Results: Nineteen patients were treated, of whom 11 patients (57.9%) had HCV genotype 1. Fourteen patients were asymptomatic. An SVR was achieved in 74% of patients and the SVR rate was 100 and 83.3%, respectively, in genotype 1 and non-1 infected patients treated with a dosage Conclusions: The rate of SVR was independent of the HCV genotype and was significantly associated by multivariate analysis only with the higher PEG-IFN dosage. Early identification and treatment of AHC is likely to decrease the burden of chronic hepatitis, especially when caused by HCV genotype 1.
Received April 27, 2005
Revised October 10, 2005
Accepted November 20, 2005
Brief report
Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C
Francesco G. De Rosa 1 *,
Olivia Bargiacchi 1,
Sabrina Audagnotto 1,
Silvia Garazzino 1,
Giuseppe Cariti 1,
Riccardo Raiteri 1,
and
Giovanni Di Perri 1
Francesco G. De Rosa, E-mail: francescogiuseppe.derosa{at}unito.it
Abstract 
1.33 µg/kg, compared with 40 and 50%, respectively, in those who received a lower dosage. An SVR was significantly associated by multivariate analysis only with PEG-IFN dosage 1.33 µg/kg/week. No significant association was found with any viral genotype.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Wiegand, K. Deterding, M. Cornberg, and H. Wedemeyer Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon {alpha} J. Antimicrob. Chemother., November 1, 2008; 62(5): 860 - 865. [Abstract] [Full Text] [PDF]
|
|